Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

tremelimumab-actl

View Patient Information
A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab-actl binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CTLA4 human monoclonal antibody CP-675,206
ticilimumab
tremelimumab
US brand name:Imjudo
Code name:CP-675
CP-675,206
CP-675206
Chemical structure:immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search